A Registry-Based Observational Study to Assess Maternal, Pregnancy, and Infant Outcomes Following Exposure to Ixekizumab (I1F-MC-B010)

Study identification

• EU PAS number:
  EUPAS32751
• Study ID:
  32752
• Official title and acronym:
  A Registry-Based Observational Study to Assess Maternal, Pregnancy, and Infant Outcomes Following Exposure to Ixekizumab (I1F-MC-B010)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study status:
  Planned

Research institutions and networks

Institutions

Eli Lilly and Company

Study timelines

Date when funding contract was signed

Actual: 31/10/2018

Study start date

Planned: 31/12/2021

Date of final study report

Planned: 31/05/2030

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Eli Lilly & Co.

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Non-EU RMP only